M Lader

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi request reprint Addiction and the pharmacology of cannabis: implications for medicine and the law
    Malcolm Lader
    Institute of Psychiatry King s College, Denmark Hill, London SE5 8AF
    Med Sci Law 49:1-17. 2009
  2. ncbi request reprint Pharmacotherapy of mood disorders and treatment discontinuation
    Malcolm Lader
    Institute of Psychiatry, King s College London, London, UK
    Drugs 67:1657-63. 2007
  3. ncbi request reprint The effect of escitalopram on sleep problems in depressed patients
    M Lader
    Institute of Psychiatry, University of London, London, UK
    Hum Psychopharmacol 20:349-54. 2005
  4. ncbi request reprint Management of panic disorder
    Malcolm Lader
    Institute of Psychiatry, Denmark Hill, London, SE5 8AF, UK
    Expert Rev Neurother 5:259-66. 2005
  5. ncbi request reprint A NICE missed opportunity?
    Malcolm Lader
    Institute of Psychiatry, King s College London, De Crespigny Park, London, UK
    J Psychopharmacol 19:136-8. 2005
  6. ncbi request reprint Antiparkinsonian medication and pathological gambling
    Malcolm Lader
    Institute of Psychiatry, King s College, London, England
    CNS Drugs 22:407-16. 2008
  7. doi request reprint Effectiveness of benzodiazepines: do they work or not?
    Malcolm Lader
    P056, Institute of Psychiatry, King s College, London, Denmark Hill, London, SE5 8AF, UK
    Expert Rev Neurother 8:1189-91. 2008
  8. ncbi request reprint Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study
    Malcolm Lader
    Institute of Psychiatry, University of London, London, SE5 8AF, UK
    Depress Anxiety 19:241-8. 2004
  9. doi request reprint Withdrawing benzodiazepines in primary care
    Malcolm Lader
    Institute of Psychiatry, King s College London, London, England
    CNS Drugs 23:19-34. 2009
  10. ncbi request reprint Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target
    Malcolm Lader
    PO Box 56, Institute of Psychiatry, Denmark Hill, London SE5 8AF, United Kingdom
    Eur Neuropsychopharmacol 17:743-55. 2007

Detail Information

Publications19

  1. ncbi request reprint Addiction and the pharmacology of cannabis: implications for medicine and the law
    Malcolm Lader
    Institute of Psychiatry King s College, Denmark Hill, London SE5 8AF
    Med Sci Law 49:1-17. 2009
    ..Suggestions are made for further research into the pharmacology and toxicology of CBD. Such data may also point to a more rational evidence-based approach to the legal control of cannabis preparations...
  2. ncbi request reprint Pharmacotherapy of mood disorders and treatment discontinuation
    Malcolm Lader
    Institute of Psychiatry, King s College London, London, UK
    Drugs 67:1657-63. 2007
    ..To this end, physicians should educate themselves and the public about discontinuation and withdrawal, so that these clinical features can be put in a realistic context...
  3. ncbi request reprint The effect of escitalopram on sleep problems in depressed patients
    M Lader
    Institute of Psychiatry, University of London, London, UK
    Hum Psychopharmacol 20:349-54. 2005
    ..A further prospective study is needed to establish this useful clinical effect in insomniac depressives...
  4. ncbi request reprint Management of panic disorder
    Malcolm Lader
    Institute of Psychiatry, Denmark Hill, London, SE5 8AF, UK
    Expert Rev Neurother 5:259-66. 2005
    ..Cognitive behavioral therapy is the psychologic treatment of first choice. The methods of combining drug and nondrug treatments need careful and thorough exploration...
  5. ncbi request reprint A NICE missed opportunity?
    Malcolm Lader
    Institute of Psychiatry, King s College London, De Crespigny Park, London, UK
    J Psychopharmacol 19:136-8. 2005
  6. ncbi request reprint Antiparkinsonian medication and pathological gambling
    Malcolm Lader
    Institute of Psychiatry, King s College, London, England
    CNS Drugs 22:407-16. 2008
    ..The mechanism of this adverse effect is believed to be excessive dopaminergic stimulation but probably not specifically involving D3 receptors. A parallel to addictive behaviour with stimulant drugs has been noted...
  7. doi request reprint Effectiveness of benzodiazepines: do they work or not?
    Malcolm Lader
    P056, Institute of Psychiatry, King s College, London, Denmark Hill, London, SE5 8AF, UK
    Expert Rev Neurother 8:1189-91. 2008
    ..I point out the changes in diagnostic criteria over the years and the lack of accepted methods of assessing estimates of effectiveness in clinical practice. Excessive prescribing of these controversial drugs is likely to continue...
  8. ncbi request reprint Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study
    Malcolm Lader
    Institute of Psychiatry, University of London, London, SE5 8AF, UK
    Depress Anxiety 19:241-8. 2004
    ..It is concluded that doses of 5-20 mg escitalopram are effective and well tolerated in the short- and long-term treatment of generalised SAD...
  9. doi request reprint Withdrawing benzodiazepines in primary care
    Malcolm Lader
    Institute of Psychiatry, King s College London, London, England
    CNS Drugs 23:19-34. 2009
    ..Some of the principles of withdrawing benzodiazepines are listed. Antidepressants may be helpful, as may some symptomatic remedies. Care must be taken not to substitute one drug dependence problem for the original one...
  10. ncbi request reprint Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target
    Malcolm Lader
    PO Box 56, Institute of Psychiatry, Denmark Hill, London SE5 8AF, United Kingdom
    Eur Neuropsychopharmacol 17:743-55. 2007
    ..Disturbances in circadian rhythms may be an integral part of depressive mechanisms, and normalising them via an innovative mechanism of antidepressant action may be a fruitful avenue in the search for improved antidepressant agents...
  11. ncbi request reprint A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder
    M Lader
    Institute of Psychiatry, London, UK
    Psychopharmacology (Berl) 139:402-6. 1998
    ..75 versus 7.23 points, respectively). Secondary variables such as CGI and self-ratings (HAD scale) showed both hydroxyzine and buspirone to be more efficacious than placebo. Thus, hydroxyzine is a useful treatment for GAD...
  12. ncbi request reprint Classification and drug treatment of the anxiety disorders
    Malcolm Lader
    Institute of Psychiatry, King s College London, UK
    Seishin Shinkeigaku Zasshi 106:1242-53. 2004
  13. ncbi request reprint Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions
    Dan J Stein
    University of Cape Town, South Africa and University of Florida, Gainesville, USA
    Eur Neuropsychopharmacol 16:33-8. 2006
    ..This paper examines data from a fixed-dose trial of escitalopram versus paroxetine, in order to determine the differential effects of these agents on symptom dimensions in social anxiety disorder (SAD)...
  14. ncbi request reprint Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions
    Dan J Stein
    MRC Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa
    Depress Anxiety 20:175-81. 2004
    ..A six-factor model of social anxiety symptoms is supported by the distinctive association between these symptom dimensions and different areas of disability, but did not predict differential response to escitalopram...
  15. ncbi request reprint Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder
    Paolo Meoni
    Wyeth Research, Paris, France
    Depress Anxiety 19:127-32. 2004
    ....
  16. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
    ..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment...
  17. ncbi request reprint Mortality in schizophrenia
    Pascal Auquier
    Departement de sante publique, Faculte de Medecine, La Timone, Marseille, France
    Pharmacoepidemiol Drug Saf 15:873-9. 2006
    ..The purpose of this article is to describe the current status of knowledge on excess mortality in schizophrenia and its causative factors, and to expand upon previous work evaluating approaches that may reduce mortality rates...
  18. ncbi request reprint Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
    ..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
  19. ncbi request reprint Mortality in schizophrenia
    Pascal Auquier
    Servíce Santé Publique, Faculte de Medecine, France
    Pharmacoepidemiol Drug Saf 16:1308-12. 2007
    ..Careful selection of antipsychotic drugs, some of which are associated with side effects such as weight gain and cardiac disorders, will also help reduce co-morbidity and mortality among patients with schizophrenia...